Alert on Falsified Drug Series: AATC

According to information received from F. Hoffmann-La Roche, there is a report of a falsified series of the drug Tezentric (atezolizumab), concentrated solution for injection, 60 mg/ml, in a 20 ml glass vial, series N H0044B01. The company has identified significant differences in the packaging and labeling compared to the original product, also noting that the Tezentric drug with series number H0044B01 (labeled as N B0044 on the vial) has never been produced by the company.

The Ministry of Health and Labor Inspection of the Republic of Armenia has stated: “There are no data on the Tezentric (atezolizumab) series N H0044B01 in the database of drugs that have passed the import examination in accordance with the prescribed legal procedure. Dear citizens, please be cautious and avoid using the drug with series N7796,” the announcement emphasizes.